ADHD Combination Treatment Addresses Memory Deficits Better Than Monotherapy
Researchers investigated whether d-methylphenidate and guanfacine show promise as a combination treatment for ADHD in children.
All articles by Heather R. Johnson
Response to Schizophrenia Treatment Varies Based on Genes
Investigators searched PubMed, Cochrane Library, Medline, Embase, CNKI, Weipu, and Wanfang databases for eligible studies through March 2022.
Targeting Slowed Psychomotor Response May Help Prevent Depression Relapse
Researchers explored the neurobiology related to reward-based reinforcement learning and psychomotor retardation in patients in remission from MDD.
Can Machine Learning Better Stratify Patients With Early Psychosis?
To better identify and categorize symptoms, researchers developed a machine learning model to “redraw boundaries” within early psychosis.
Bipolar Disorder and Schizophrenia Show Similar Response Inhibition
Researchers sought to find mechanisms of impaired impulsivity control in patients with BD responding to emotion and compare them to patients with schizophrenia.
Antidepressants May Improve Sleep Quality in Women With Depression
Researchers assessed the percentages of REM and Stage 3 sleep, controlling for age and sleep medication use.
Brexpiprazole May Improve Functioning in Patients With Schizophrenia
Some patients with schizophrenia may experience residual symptoms when treated with antipsychotics, due in part to their side effects. This analysis aims to examine both short-term improvement and residual symptoms of prescribed medication.
Brodalumab Equally Effective in Treating Scalp, Nail Psoriasis in Men and Women
The efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis is investigated.
Researchers Provide Insight Into Affective Lability in Psychosis
Researchers are exploring affective lability as a therapeutic target for bipolar disorder, but limited evidence exists on its prevalence and impact among people with schizophrenia and other psychosis spectrum disorders.
People with Schizophrenia at High Risk of Dying from COVID-19
With people who have major psychiatric disorders being more likely to have comorbidities which could lead to worse results concerning COVID-19, researchers using a US database assessed the odds of testing positive for COVID-19, as well as mortality from COVID-19.
- Loading...
Loading...
Next post in Schizophrenia Information Center
Loading... 
Loading...